Following a limited submission
AWMSG advice |
|||
| Status: Recommended | |||
Ursodeoxycholic acid (Ursofalk®) is recommended for use within NHS Wales for the treatment of hepatobiliary disorders associated with cystic fibrosis in children aged 1 month to 18 years. |
|||
|
|||
Medicine details |
|||
| Medicine name | ursodeoxycholic acid (Ursofalk®) | ||
| Formulation | 250 mg hard capsules; 500 mg film-coated tablet; 250 mg/5 ml oral suspension | ||
| Reference number | 2610 | ||
| Indication | Treatment of hepatobiliary disorders associated with cystic fibrosis in children aged 1 month to 18 years |
||
| Company | Dr Falk Pharma UK Ltd | ||
| BNF chapter | Gastro-intestinal system | ||
| Submission type | Limited | ||
| Status | Recommended | ||
| Advice number | 1016 | ||
| NMG meeting date | 16/03/2016 | ||
| AWMSG meeting date | 20/04/2016 | ||
| Ratification by Welsh Government | 29/04/2016 | ||
| Date of issue | 03/05/2016 | ||
| Date of last review | 08/02/2019 | ||